Carrillo ER, Sánchez ZMJ, Elizondo AS

Language: Spanish
References: 19
Page: 98-104
PDF size: 63.30 Kb.

Text Extraction

No abstract

REFERENCES

1. Ford, Giles, Dietz. Prevalence of the Metabolic Syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.

2. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

3. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different name, different concepts, and different goals. Endocrinol Metabolism Clin 2004; 33: 2.

4. Han TS, Sattar N, Williams K, Gonzalez-Villalpando. C, Lean MJ, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.

5. González, Alexanderson, Alvarado y col. Consenso mexicano sobre el tratamiento integral del síndrome metabólico. Med Int Mex 2002; 18: 12-41.

6. González, Alexanderson, Alvarado y col. Consenso Mexicano de resistencia a la Insulina y Síndrome Metabólico. Rev Mex Cardiol 1999; 10: 3-18.

7. Velásquez-Monrroy O, Rosas PM, Lara E, Pastelin HG, grupo ENSA 2000, Attie F, Tapia-Conyer R: Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch CardiolMex 2002; 72: 71-84.

8. Aguilar, Rojas, Gómez et al. Prevalence of the Syndrome Diagnosed using the World Health Organization criteria in a Nation-wide survey in México. Diabetes 2002; 51 (Suppl 2) A218.

9. Aguilar, Rojas, Gómez et al. El Síndrome Metabólico: un concepto en evolución. Gac Med Mex 2004; 140: S41-48.

10. Devavaj S, Rosenson R, Jialal I. Metabolic syndrome: an appraisal of the proinflammatory and procoagulant status. 2004; 33: 2.

11. Assman G, Nofer JR, Schutle. Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin N Am 2004; 33: 377-97.

12. Alberti, Zimmet. Definitions, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of Diabetes mellitus provisional report of a WHO consultation. Diabetes Care. 2004; 15: 539-553.

13. Danesh J, Whincup P, Walher M et al. Low grade inflammation and coronary heart disease: prospective study and adapted meta-analyses. BMJ 2000; 321: 199-204.

14. Cardona, Carranza, Hernández. Modificaciones del estilo de vida y tratamiento farmacológico de la hipertensión arterial sistémica. Rev Mex Cardiol 2001; 12: 25-36.

15. Moregraga et al. Definición, causas, clasificación, epidemiología y prevención primaria de la Hipertensión arterial sistémica. Rev Mex Cardiol 2001; 12: 9-18.

16. Joint National Committe on Prevention, Detection, Evaluation and Treatment of High Blood Presure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289: 2534-2573.

17. Adler, Stratton, Andrew et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-19.

18. Messerli. Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens 2001; 14: 125-165.

19. Kaplan. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med. 2001; 135: 1079-1083.